EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions

Kostas A Papavassiliou iD, Dimitrios J Stravopodis iD, Vassiliki A Gogou iD, Athanasios G Papavassiliou iD

American Journal of Respiratory and Critical Care Medicine · 01.06.2026 · 212 (6) · 1100-1114

DOI: 10.1093/ajrccm/aamaf124 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, online erschienen am 23.01.2026. Verfasst von Kostas A Papavassiliou und 3 weiteren Autor:innen. Beteiligte Einrichtung: First University Department of Respiratory Medicine, "Sotiria" Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens…. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Small Cell Lung Carcinoma, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with dismal prognosis. Although immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer, their impact in SCLC has been modest, with only 2–3 months’ improvement in median survival. This paradox persists despite SCLC’s high tumor mutational burden, suggesting complex, multifactorial resistance mechanisms. Here we critically review the latest advances in understanding immunotherapy resistance in SCLC. We highlight tumor-intrinsic immune escape mechanisms, including genetic drivers, MHC class I downregulation, and epigenetic repression, as well as the profoundly immunosuppressive tumor microenvironment. We also examine the evolving classification of SCLC into molecular subtypes, which reveals distinct immunogenic landscapes with potential predictive value for immunotherapy response. Importantly, we integrate a comprehensive update on ongoing and recently reported clinical trials that aim to restore immune responsiveness, ranging from combination ICI regimens to novel strategies involving epigenetic modulators, antigen presenting pathway agonists, and bispecific T-cell engagers. Finally, we discuss translational strategies to overcome immunotherapy resistance and outline a precision immunotherapy roadmap, arguing for biomarker-guided and subtype-stratified clinical trial design. By synthesizing mechanistic, translational, and clinical perspectives, this review provides a framework for rational therapeutic innovation in SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsImmunotherapySmall Cell Lung CarcinomaDrug Resistance, NeoplasmImmune Checkpoint InhibitorsHumansTumor MicroenvironmentTumor Escape

Stichwörter der Autor:innen

epigenetic modulationimmune checkpoint inhibitorsimmunotherapy resistancemolecular subtypessmall cell lung cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • First University Department of Respiratory Medicine, "Sotiria" Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Section of Cell Biology and Biophysics, Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Kostas A Papavassiliou, Dimitrios J Stravopodis, Vassiliki A Gogou, Athanasios G Papavassiliou

Zitieren

APA

Papavassiliou, K. A., Stravopodis, D. J., Gogou, V. A., & Papavassiliou, A. G. (2026). Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions. American Journal of Respiratory and Critical Care Medicine, 212(6), 1100-1114. https://doi.org/10.1093/ajrccm/aamaf124

Vancouver

Papavassiliou KA, Stravopodis DJ, Gogou VA, Papavassiliou AG. Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions. American Journal of Respiratory and Critical Care Medicine. 2026;212(6):1100-1114. doi:10.1093/ajrccm/aamaf124

BibTeX
@article{Papavassiliou2026,
  author = {Papavassiliou, Kostas A and Stravopodis, Dimitrios J and Gogou, Vassiliki A and Papavassiliou, Athanasios G},
  title = {Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions},
  journal = {American Journal of Respiratory and Critical Care Medicine},
  year = {2026},
  volume = {212},
  number = {6},
  pages = {1100--1114},
  doi = {10.1093/ajrccm/aamaf124}
}
Kostenlos starten →